Related Experiment Video

Updated: Jul 14, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes

Elena Galletti1, Matteo Magnani, Michela L Renzulli

  • 1Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via Alcide de Gasperi, 2, I-53100 Siena, Italy.

Chemmedchem
|May 29, 2007
PubMed

Insights

New taxane derivatives show promise in overcoming cancer resistance. These novel compounds target multidrug resistance (MDR) and microtubule alterations, offering hope for treating resistant tumors.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Taxanes, including paclitaxel and docetaxel, are vital anticancer agents.
  • Clinical efficacy is hampered by multidrug resistance (MDR) and microtubule alterations.
  • Development of novel taxanes is crucial for overcoming treatment resistance.

Purpose of the Study:

  • To review molecular mechanisms of taxane resistance.
  • To highlight advances in developing new taxane derivatives against resistant tumors.
  • To discuss taxanes with activity against MDR and microtubule-altered cancer cells.

Main Methods:

  • Literature review of taxane resistance mechanisms.
  • Analysis of novel natural and synthetic taxane derivatives.
  • Evaluation of taxane activity against MDR and tubulin-mutated cancer models.

Main Results:

  • Several novel taxane derivatives exhibit MDR-inhibiting properties or enhanced cytotoxicity.
  • Newer taxanes demonstrate efficacy against cancer cells with altered tubulin/microtubule systems.
  • Understanding resistance mechanisms guides the design of improved taxanes.

Conclusions:

  • Novel taxane derivatives offer potential therapeutic strategies for resistant cancers.
  • Targeting MDR and microtubule alterations is key to overcoming taxane resistance.
  • Continued research into taxane development is essential for advancing cancer treatment.

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...